Text Size

Epidemiology and Control of Mansonella Perstans Infection in Uganda

This study has been completed.
Sponsor:
Collaborator:
Vector control Division, Kampala, Uganda
Information provided by:
DBL -Institute for Health Research and Development
ClinicalTrials.gov Identifier:
NCT00215280
First received: September 21, 2005
Last updated: April 19, 2007
Last verified: April 2007
History of Changes
  Purpose

Mansonella perstans (M. perstans) infection is widespread in Uganda. Knowledge about the epidemiology of this infection, and of the morbidity it induces is poor, and no effective treatment is available. The study aims at providing data on diagnostic, epidemiological, morbidity and treatment aspects of M. perstans infections in Uganda.


Condition Intervention
Mansonelliasis
Pruritus
Lymphoedema
Abdominal Pains
 Drug: ivermectin and albendazole

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Studies on the Epidemiology and Control of Mansonella Perstans Infection in Uganda

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by DBL -Institute for Health Research and Development:

Primary Outcome Measures:
  • microfilariae periodicity patterns
  • epidemiology of M. perstans at community level
  • clinical spectre among infected
  • reduction in microfilaraemia

Secondary Outcome Measures:
  • treatment effect on clinical manifestations

Estimated Enrollment: 1000
Study Start Date: November 2005
Estimated Study Completion Date: February 2006
Detailed Description:

Overall objective: to investigate diagnostic, epidemiological and treatment aspects of M. perstans in Uganda with relevance to control

Specific objectives:

  1. To establish the pattern of diurnal periodicity of M. perstans microfilaraemia in humans
  2. To establish the patterns of M. perstans microfilaraemia and possible clinical manifestations related to this infection in two communities with medium to high endemicity
  3. To determine the efficacy of ivermectin alone and the combination of ivermectin and albendazole on M. perstans microfilaraemia.
  Eligibility

Ages Eligible for Study:   5 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Individuals >= 5 years with or without M. perstans infection

Exclusion Criteria:

  • Individuals < 5 years
  • Pregnant women
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00215280

Locations
Uganda
Luwero
Luwero and Mukono, Luwero and Mukono Districts, Uganda
Sponsors and Collaborators
DBL -Institute for Health Research and Development
Vector control Division, Kampala, Uganda
Investigators
Principal Investigator: Asanta M Asio, Msc Vector control Division, Kampala, Uganda
  More Information

Additional Information:
Related Info  This link exits the ClinicalTrials.gov site

No publications provided by DBL -Institute for Health Research and Development

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

ClinicalTrials.gov Identifier: NCT00215280     History of Changes
Other Study ID Numbers: MV917090205
Study First Received: September 21, 2005
Last Updated: April 19, 2007
Health Authority: Uganda: National Council for Science and Technology

Keywords provided by DBL -Institute for Health Research and Development:
Mansonella perstans
microfilaraemia
ivermectin
albendazole
Uganda

Additional relevant MeSH terms:
Abdominal Pain
Dipetalonema Infections
Lymphedema
Mansonelliasis
Pruritus
Pain
Signs and Symptoms
Signs and Symptoms, Digestive
Filariasis
Spirurida Infections
Secernentea Infections
Nematode Infections
Helminthiasis
Parasitic Diseases
Lymphatic Diseases
 Skin Diseases
Skin Manifestations
Albendazole
Ivermectin
Anticestodal Agents
Antiplatyhelmintic Agents
Anthelmintics
Antiparasitic Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Antiprotozoal Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators

ClinicalTrials.gov processed this record on May 16, 2013